VALNEVA USA, INC.

Lobbying for VALNEVA USA, INC. · Vaccine company

Filing 4th Quarter - Termination

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Dec 4, 2025

Expenses

$120,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Maryland

Representation ended

Dec 3, 2025

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 3

Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 1

Health Issues

Coverage for all adult vaccines (regulation related to Public Health Service Act, Sec 2713); Appropriations related to CDC report on arbovirus threat; Appropriations related to funding the State Stockpile Grant program; Issues related to Strategic National Stockpile procurement regarding new emerging infection diseases and in relation to the Preparedness Act (PAHPA) reauthorization; Issues related to the FDA's Priority Review Voucher; Issues related to reauthorization of the publican health emergency medical countermeasures enterprise; Enhancing immunization access for military dependents

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.